NASDAQ$DYN
Dyne Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported third quarter financial results and provided an update on significant progress for ACHIEVE and DELIVER trials and upcoming clinical milestones.
Dyne Therapeutics reported progress in their ACHIEVE and DELIVER trials, with favorable safety profiles supporting dose escalation. Initial data from both trials, including biomarker and functional outcome data, is expected in early January 2024. The company's cash, cash equivalents, and marketable securities were $157.8 million as of September 30, 2023, expected to fund operations through 2024. The net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.
- ACHIEVE and DELIVER trials have enrolled over 72 patients with over 300 doses administered, showing favorable safety profiles for DYNE-101 and DYNE-251.
- Initial data from ACHIEVE and DELIVER trials, including splicing, myotonia, and dystrophin data, will be presented in early January 2024.
- Enrollment is complete in the ACHIEVE trial for the 1.8 mg/kg and 3.4 mg/kg cohorts, and the safety profile supports dose escalation to cohort 3 (up to 6.8 mg/kg).
- Enrollment is complete in the DELIVER trial through the 10 mg/kg cohort, and the safety profile supports dose escalation to cohort 6 (up to 20 mg/kg).
Headline financials
Revenue & EPS history
Dyne Therapeutics · Revenue · Quarterly
$0
Forward guidance
Dyne Therapeutics anticipates reporting initial data from the ACHIEVE and DELIVER trials in early January 2024, and their current cash position is expected to fund operations through 2024.
Tailwinds
- Initial data from ACHIEVE trial in early January 2024 will include safety and tolerability data from multiple cohorts.
- Initial data from ACHIEVE trial will include splicing data and analysis of the video hand opening time (vHOT) myotonia functional assessment from at least the 1.8 mg/kg cohort at 6 months.
- Initial data from DELIVER trial in early January 2024 will include safety and tolerability data from multiple cohorts.
- Initial data from DELIVER trial will include Dystrophin expression data from the 5 mg/kg cohort at 6 months.
- Cash, cash equivalents and marketable securities are anticipated to fund operations through 2024.
Headwinds
- Uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials.
- Uncertainties as to the availability and timing of results from preclinical studies and clinical trials.
- The timing of and Dyne’s ability to initiate and enroll patients in clinical trials.
- Whether results from preclinical studies and clinical trials will be predictive of the results of later preclinical studies and clinical trials.
- Whether Dyne’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+1.8%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+3.0%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+21.3%
Q3 2024
Best reaction
-6.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +3.6% | -4.9% | +15.9% | |
| Q3 2025 | -2.8% | -14.0% | -5.8% | |
| Q2 2025 | -1.3% | +7.9% | +47.7% | |
| Q1 2025 | +1.1% | +3.6% | +30.1% | |
| Q4 2024 | -4.5% | -13.8% | -17.0% | |
| Q3 2024 | +21.3% | +0.9% | -9.0% | |
| Q2 2024 | +0.5% | +5.7% | -22.0% | |
| Q1 2024 | +1.0% | -0.7% | +23.4% | |
| Q4 2023 | -3.4% | -9.2% | -4.5% | |
| Q3 2023 | +6.5% | +24.3% | +66.0% | |
| Q2 2023 | -1.8% | -15.6% | +0.1% | |
| Q1 2023 | -4.0% | -4.6% | -7.4% | |
| Q4 2022 | +10.1% | +8.3% | -15.5% | |
| Q3 2022 | +1.6% | -4.9% | +15.8% | |
| Q2 2022 | +4.3% | +1.1% | +1.0% | |
| Q1 2022 | +10.5% | -16.4% | -45.0% | |
| Q4 2021 | -1.7% | -2.9% | +16.5% | |
| Q3 2021 | +2.0% | +0.7% | -10.4% | |
| Q2 2021 | +3.3% | -4.1% | -9.6% | |
| Q1 2021 | +5.1% | +0.2% | +1.9% | |
| Q4 2020 | -6.5% | -6.2% | -4.4% | |
| Q3 2020 | -5.0% | -9.6% | -1.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro